Merck and Moderna maintain a longstanding co-development partnership centered on their personalized mRNA cancer vaccine candidate combined with Keytruda, with positive Phase 3 melanoma data released on August 19, 2026, driving share gains but no ownership change. Merck has instead executed smaller acquisitions such as Terns Pharmaceuticals and Cidara Therapeutics in 2026 to bolster its post-Keytruda pipeline amid the looming patent cliff, while Moderna focuses on advancing the joint program through regulatory milestones without signals of a full merger. Trader consensus at 86.5% for no announced deal in 2026 reflects the absence of M&A filings, regulatory disclosures, or executive commentary indicating consolidation, despite sector-wide biotech deal activity. Key upcoming catalysts include further trial readouts and potential approval timelines that could sustain the collaboration without triggering a transaction.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日はい
13% 確率
新規
新規
2026/12/31
はい
13% 確率
新規
新規
2026/12/31
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a longstanding co-development partnership centered on their personalized mRNA cancer vaccine candidate combined with Keytruda, with positive Phase 3 melanoma data released on August 19, 2026, driving share gains but no ownership change. Merck has instead executed smaller acquisitions such as Terns Pharmaceuticals and Cidara Therapeutics in 2026 to bolster its post-Keytruda pipeline amid the looming patent cliff, while Moderna focuses on advancing the joint program through regulatory milestones without signals of a full merger. Trader consensus at 86.5% for no announced deal in 2026 reflects the absence of M&A filings, regulatory disclosures, or executive commentary indicating consolidation, despite sector-wide biotech deal activity. Key upcoming catalysts include further trial readouts and potential approval timelines that could sustain the collaboration without triggering a transaction.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
マーケット開始日： Aug 19, 2026, 3:58 PM ET
音量
$0終了日
2026/12/31マーケット開始日
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a longstanding co-development partnership centered on their personalized mRNA cancer vaccine candidate combined with Keytruda, with positive Phase 3 melanoma data released on August 19, 2026, driving share gains but no ownership change. Merck has instead executed smaller acquisitions such as Terns Pharmaceuticals and Cidara Therapeutics in 2026 to bolster its post-Keytruda pipeline amid the looming patent cliff, while Moderna focuses on advancing the joint program through regulatory milestones without signals of a full merger. Trader consensus at 86.5% for no announced deal in 2026 reflects the absence of M&A filings, regulatory disclosures, or executive commentary indicating consolidation, despite sector-wide biotech deal activity. Key upcoming catalysts include further trial readouts and potential approval timelines that could sustain the collaboration without triggering a transaction.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
音量
$0終了日
2026/12/31マーケット開始日
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a longstanding co-development partnership centered on their personalized mRNA cancer vaccine candidate combined with Keytruda, with positive Phase 3 melanoma data released on August 19, 2026, driving share gains but no ownership change. Merck has instead executed smaller acquisitions such as Terns Pharmaceuticals and Cidara Therapeutics in 2026 to bolster its post-Keytruda pipeline amid the looming patent cliff, while Moderna focuses on advancing the joint program through regulatory milestones without signals of a full merger. Trader consensus at 86.5% for no announced deal in 2026 reflects the absence of M&A filings, regulatory disclosures, or executive commentary indicating consolidation, despite sector-wide biotech deal activity. Key upcoming catalysts include further trial readouts and potential approval timelines that could sustain the collaboration without triggering a transaction.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問